Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Baxter | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Baxter

Revenues up 15% boosted by Gambro acquisition

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Baxter

1Q Revenues: $4.0 billion (+15%)

1Q Earnings: $556 million (+1%)

Comments: BioScience revenues were $1.6 billion, up 5%, driven by growth of ADVATE and FEIBA, improved U.S. sales of plasma-based therapeutics including GAMMAGARD LIQUID, and milestone payments related to ongoing collaborations with governments on flu vaccine development. Medical Products sales increased 22% to $2.3 billion, augmented by the Gambro acquisition, which contributed $400 million. R&D expenses were $313 million up 27%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters